Clinical Trials Directory

Trials / Terminated

TerminatedNCT00508911

A Study To Evaluate The Effect Of GW876008 On The Pharmacokinetics Of Oral Contraceptive Pills

An Open-label, Repeat-dose, Single-sequence Study to Investigate the Effects of Once-daily Repeat Oral Administration of GW876008 125mg on the Pharmacokinetics of the Combined Oral Contraceptive in Female Volunteers

Status
Terminated
Phase
Phase 1
Study type
Interventional
Enrollment
4 (actual)
Sponsor
GlaxoSmithKline · Industry
Sex
Female
Age
18 Years – 45 Years
Healthy volunteers
Accepted

Summary

This study will be conducted in healthy female volunteers to investigate the effect of GW876008 on the pharmacokinetics of oral contraceptive pills.

Conditions

Interventions

TypeNameDescription
DRUGGW876008GW876008 tablets will be available as white to off-white coated tablets. Each subject will receive a single oral dose of GW876008, daily for up to 35 days in Session 2. GW876008 will be administered in the morning with a light breakfast.
DRUGCOCCOC containing ethinylestradiol 30 microgram and levonorgestrel 150 microgram will be administered in the morning with a light breakfast.

Timeline

Start date
2007-06-08
Primary completion
2007-10-22
Completion
2007-10-22
First posted
2007-07-30
Last updated
2017-08-04

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT00508911. Inclusion in this directory is not an endorsement.